| Autor: |
Lee SL; Chester Centre for Stress Research, Institute of Medicine, University of Chester, Bache Hall, Chester, CH2 1BR, UK.; University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK., Dempsey-Hibbert NC; Chester Centre for Stress Research, Institute of Medicine, University of Chester, Bache Hall, Chester, CH2 1BR, UK.; Centre for Biomedicine Research, Manchester Metropolitan University, Chester Street, Manchester, M1 5GD, UK., Vimalachandran D; Countess of Chester Hospital, Liverpool Rd, Chester, CH2 1UL, UK., Wardle TD; Countess of Chester Hospital, Liverpool Rd, Chester, CH2 1UL, UK., Sutton PA; Countess of Chester Hospital, Liverpool Rd, Chester, CH2 1UL, UK., Williams JHH; Chester Centre for Stress Research, Institute of Medicine, University of Chester, Bache Hall, Chester, CH2 1BR, UK. John.williams@chester.ac.uk. |
| Abstrakt: |
Preclinical studies are an essential stage for any pharmacological agent hoping to make its way into clinical trials. An ideal preclinical model that can accurately predict clinical response does not exist and the best that the scientific community have at the moment is to select the most relevant study model pertaining to the disease of interest from those available, which includes: cell lines, animal models, and even in-silico methodology. Currently, there is a huge gap between preclinical and clinical trial results, indicating that there is much room for improvement in developing a better model to bridge the translational gap. |
